cacospongionolide B

isolated from the sponge Fasciospongia cavernosa; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Necrosis 04/01/2003 - "Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation." 01/01/1999 - "4. In the mouse air pouch injected with zymosan, cacospongionolide B administered into the pouch, induced a dose-dependent reduction in the levels of eicosanoids and tumour necrosis factor alpha (TNFalpha) in the exudates 4 h after the stimulus. "
2.	Inflammation (Inflammations) 11/01/2006 - "Cacospongionolide B and petrosaspongiolide M are representative examples of anti-inflammatory compounds in experimental models of acute or chronic inflammation. " 01/01/1999 - "6 Cacospongionolide B is a new inhibitor of sPLA2 in vitro and in vivo, with anti-inflammatory properties in acute and chronic inflammation. "
3.	Experimental Arthritis 01/01/1999 - "5. The inflammatory response of adjuvant arthritis was reduced by cacospongionolide B, which did not significantly affect eicosanoid levels in serum, paw or stomach homogenates and did not induce toxic effects. " 01/01/1999 - "Cacospongionolide B, that is bioavailable when is given orally, reduced the elevated levels of sPLA2 present in paw homogenates of rats with adjuvant arthritis. "

1.	Secretory Phospholipases A2
2.	NF-kappa B (NF-kB)
3.	Eicosanoids
4.	Zymosan
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Enzymes
7.	petrosaspongiolide m